Open Access

FBLN5 is targeted by microRNA‑27a‑3p and suppresses tumorigenesis and progression in high‑grade serous ovarian carcinoma

  • Authors:
    • Rongrong Li
    • Huan Wu
    • Huiyang Jiang
    • Qiuman Wang
    • Zhiyuan Dou
    • Hanlin Ma
    • Shi Yan
    • Cunzhong Yuan
    • Ning Yang
    • Beihua Kong
  • View Affiliations

  • Published online on: September 3, 2020     https://doi.org/10.3892/or.2020.7749
  • Pages: 2143-2151
  • Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

High-grade serous ovarian carcinoma (HGSOC) is one of the most lethal gynecological malignancies; however, the precise molecular mechanisms have not been fully characterized. Fibulin‑5 (FBLN‑5) is an extracellular matrix (ECM) glycoprotein, and plays a crucial role in maintaining the stability of ECM structures, regulating cell proliferation and tumorigenesis. In the present study, the expression of FBLN‑5, as determined by western blot analysis and immunohistochemistry, was significantly increased in normal fallopian tube (FT) samples compared with that in HGSOC samples, and decreased FBLN5 expression was associated with unfavorable prognosis of HGSOC. Functional characterization revealed that FBLN5 overexpression significantly inhibited migration, invasion and proliferation abilities of ovarian cancer cells in vitro. Furthermore, micro (mi)RNA‑27a‑3p (miR‑27a‑3p) was revealed to be increased in HGSOC, and dual‑luciferase reporter assay indicated that miR‑27a‑3p was functioned as a negative regulator of FBLN5 by directly binding with its 3'‑untranslated region. Collectively, FBLN5 expression was associated with prognosis, proliferation, and metastasis in HGSOC. We hypothesized that FBLN5 was targeted by miR‑27a‑3p and may serve as a biomarker and provide a new therapeutic approach for the treatment of HGSOC.
View Figures
View References

Related Articles

Journal Cover

November-2020
Volume 44 Issue 5

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Li R, Wu H, Jiang H, Wang Q, Dou Z, Ma H, Yan S, Yuan C, Yang N, Kong B, Kong B, et al: FBLN5 is targeted by microRNA‑27a‑3p and suppresses tumorigenesis and progression in high‑grade serous ovarian carcinoma. Oncol Rep 44: 2143-2151, 2020
APA
Li, R., Wu, H., Jiang, H., Wang, Q., Dou, Z., Ma, H. ... Kong, B. (2020). FBLN5 is targeted by microRNA‑27a‑3p and suppresses tumorigenesis and progression in high‑grade serous ovarian carcinoma. Oncology Reports, 44, 2143-2151. https://doi.org/10.3892/or.2020.7749
MLA
Li, R., Wu, H., Jiang, H., Wang, Q., Dou, Z., Ma, H., Yan, S., Yuan, C., Yang, N., Kong, B."FBLN5 is targeted by microRNA‑27a‑3p and suppresses tumorigenesis and progression in high‑grade serous ovarian carcinoma". Oncology Reports 44.5 (2020): 2143-2151.
Chicago
Li, R., Wu, H., Jiang, H., Wang, Q., Dou, Z., Ma, H., Yan, S., Yuan, C., Yang, N., Kong, B."FBLN5 is targeted by microRNA‑27a‑3p and suppresses tumorigenesis and progression in high‑grade serous ovarian carcinoma". Oncology Reports 44, no. 5 (2020): 2143-2151. https://doi.org/10.3892/or.2020.7749